Myeloma 2016: Panel discussion on the application of genomics studies
Ray Comenzo, MD from the Tufts Medical Center, Boston, MA discusses the practical applications of genomics in multiple myeloma (MM) at the Myeloma 2016 meeting held in Boston, MA with Pieter Sonneveld, MD, PhD from Erasmus University Medical Center, Rotterdam, Netherlands and Leif Bergsagel, MD from the Mayo Clinic, Scottsdale, AZ. First, Prof Sonneveld discusses the participation of patients in clinical trials, in particular in regard to obtaining patient specimen and why these specimen are important. Prof Bergsagel then discusses the importance of MYC and the potential role in prognosis and therapy of this gene. Prof Sonneveld further discusses the Cassiopeia trial on daratumumab in the frontline setting in transplant eligible patients (NCT02541383) and he explains why this drug may be promising in refractory patients. They discuss the potential impact of monoclonal antibodies for MM and the role of proteasome inhibitor such as ixazomib and carfilzomib. Finally, they talk about the issue of the genomics of the microenvironment.